1. France Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
bioMérieux S.A.

bioMérieux S.A.

BMXMF
bioMérieux S.A.US flagOther OTC
83.31
USD
- -
- -
9.83BMarket Cap
bioMérieux S.A.
BMXMF
(Other OTC)

Recent

price

83.31

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
11.46
12.06
13.28
13.4
14.35
16.59
17.82
19.41
20.56
22.61
26.39
28.55
30.43
31.1
33.8
- -
Revenue per Share
1.35
1.34
1.14
1.39
1.14
0.93
1.52
2.02
2.18
2.31
3.42
5.08
3.84
3.03
3.67
- -
Basic EPS, GAAP
0.64
0.97
1.11
0.92
1.18
0.86
0.87
2.9
1.47
1.14
2.58
4.52
1.6
0.91
2.73
- -
Free Cash Flow per Basic Share
0.31
0.33
0.33
0.33
0.33
0.33
0.33
0.33
0.34
0.35
0.19
0.62
0.86
0.85
0.85
- -
Dividend per Share
1.44
1.44
1.24
1.49
1.24
1.03
1.62
2.12
2.28
2.41
3.52
5.18
3.94
3.13
3.77
- -
Book Value per Share
5.62
4.71
5.84
6.86
4.15
4.79
5.58
7.32
7.41
9.24
12.03
17.61
18.7
21.37
25.38
- -
Tangible Book Value per Share
118
118
118
118
118
118
118
118
118
118
118
118
118
118
118
- -
Basic Weighted Avg Shares
1,357
1,427
1,570
1,588
1,698
1,965
2,103
2,288
2,421
2,675
3,118
3,376
3,589
3,675
3,980
4,070
Sales/Revenue/Turnover
18.69
18.05
16.58
16.52
13.35
13.23
14.16
14.63
15.02
13.85
19.64
25
17.43
15.48
16.03
17.07
Operating Margin (%)
88
85
94
91
105
120
143
140
177
190
211
248
248
259
302
307
Depreciation Expense
160
158
134
164
135
110
179
238
256
273
404
601
452
358
432
398
Net Income, GAAP
33.72
32.48
39.98
32.2
27.57
37.32
30.78
18.63
20.31
22.4
23.17
22.67
24.13
26.17
26.64
24.5
Effective Tax Rate (%)
11.79
11.08
8.56
10.35
7.94
5.62
8.52
10.41
10.59
10.2
12.97
17.8
12.61
9.73
10.86
9.77
Profit Margin (%)
309
218
356
731
416
413
423
630
518
268
738
1,237
1,086
1,118
1,367
1,476
Working Capital
8
13
10
305
306
309
365
391
525
154
352
363
318
355
349
330
LT Debt
976
1,076
1,160
1,267
1,389
1,503
1,621
1,737
2,002
2,255
2,481
3,164
3,643
3,752
4,211
4,106
Total Equity
17.56
14.27
11.08
10.95
8.75
8.1
9.32
11.45
10.79
9.47
14.62
17.96
11.18
9.16
9.55
10.35
Return on Invested Capital (%)
75
55.24
44.34
39.11
26.11
23.71
33.28
36.93
31.89
30.46
45.34
58.9
43.77
42.6
49.32
45.17
Return on Capital (%)
96.79
92.79
84.9
101.83
83.48
82.03
114.22
107.93
98.9
98.59
115.35
116.78
83.97
85.76
106.22
93.12
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.84%
11.08%
-2.49%
Free Cash Flow
49.61%
41.66%
40.93%
Net Income, GAAP
17.31%
3.16%
-8.03%
Sales/Revenue/Turnover
7.63%
5.51%
2.26%
Total Cash Common Dividend
- -
- -
5.89%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3,675
2024
- -
- -
- -
- -
3,980
2025
- -
- -
- -
- -
4,070

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3.03
2024
- -
- -
- -
- -
3.67
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.85
2024
- -
- -
- -
- -
0.85
2025
- -
- -
- -
- -
- -
Similar Companies
Danaher Corporation (DHR-PB)
Access Bio, Inc. (950130.KQ)
Imagion Biosystems Limited (IBX.AX)
Sotera Health Company (SHC)
SQI Diagnostics Inc. (SQIDF)
Mainz Biomed B.V. (MYNZ)
Business
bioMérieux S.A. (Ticker: BMXMF) develops, manufactures and markets in vitro diagnostic (IVD) solutions for medical and industrial applications worldwide. The company offers a broad portfolio of diagnostic systems, reagents and software; including molecular biology tests such as BioFire® multiplex PCR panels for infectious disease detection, immunoassay systems like VIDAS® for antigen/antibody assays, microbiology automation platforms including PREVI® Isola and VITEK® 2 for microbial identification and susceptibility testing, and quality control products under the API® and BioBall® brands. It serves clinical laboratories, hospitals, blood banks, pharmaceutical and food industries with solutions focused on infectious diseases, oncology, cardiovascular conditions, sepsis management, and industrial testing for contaminants in food, water and pharmaceuticals; operating in over 150 countries with manufacturing sites in Europe, North America and Asia. Founded in 1963 and headquartered in Marcy l'Etoile, near Lyon, France, bioMérieux operates through subsidiaries like BioFire Diagnostics in the US and focuses on key segments including clinical diagnostics (80% of sales), industrial applications and innovative technologies like syndromic testing and artificial intelligence integration. In the last two years, bioMérieux expanded its offerings through the launch of new BioFire® panels for respiratory and gastrointestinal pathogens amid heightened demand post-COVID, formed strategic partnerships with health authorities for antimicrobial resistance surveillance, and completed acquisitions to strengthen molecular diagnostics capabilities; additionally, the company announced a major reorganization in late 2024 to streamline its industrial division and enhance digital health services integration.

Company News

APIChat

  • seekingalpha.com

    bioMérieux S.A. (BMXXY) Q1 2026 Sales/Trading Call Transcript

  • defenseworld.net

    Analyzing HealthEquity (NASDAQ:HQY) and bioMerieux (OTCMKTS:BMXMF)

  • defenseworld.net

    bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – Time to Buy?

  • seekingalpha.com

    bioMérieux S.A. (BMXXY) Q4 2025 Earnings Call Transcript

  • defenseworld.net

    bioMerieux (OTCMKTS:BMXMF) Sees Unusually-High Trading Volume – Time to Buy?

  • seekingalpha.com

    bioMérieux S.A. (BMXXY) Analyst/Investor Day Transcript

  • seekingalpha.com

    bioMérieux S.A. (BMXMF) Q4 2024 Earnings Call Transcript

  • seekingalpha.com

    bioMérieux S.A. (BMXMF) Q2 2024 Earnings Call Transcript

  • seekingalpha.com

    bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2021 Results - Earnings Call Transcript

  • seekingalpha.com

    bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q3 2021 Results - Earnings Call Transcript

  • seekingalpha.com

    bioMérieux: Pioneering In Vitro Diagnostics

  • seekingalpha.com

    bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2020 Results - Earnings Call Transcript

  • zacks.com

    4 Top Medical Services Stocks to Beat COVID-19 Resurgence Crisis